ArticleJournal of thoracic disease2025
Midterm outcomes of concomitant ascending aorta replacement with rapid deployment aortic valve replacement.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aortic valve replacement (AVR) frequently accompanies concomitant ascending aorta replacement. This study was conducted to evaluate the early and midterm outcomes of patients who underwent AVR with rapid-deployment valve (RDAVR) and concomitant ascending aorta replacement compared to those who underwent isolated RDAVR. Methods: From June 2016 to June 2023, 130 patients who underwent RDAVR with concomitant ascending aorta replacement (Ao-AVR group) and 108 patients who underwent isolated RDAVR (Iso-AVR group) were enrolled in this study. Early and midterm outcomes were compared between the groups. Multivariate analysis was performed to identify the risk factors associated with all-cause mortality. Results: Ao-AVR group was younger and less morbid than Iso-AVR group. Bicuspid aortic valvulopathy was the main etiology in Ao-AVR group (71.5%), whereas degenerative calcific valvulopathy was the main etiology in Iso-AVR group (55.6%). Cardiopulmonary bypass time and aortic cross-clamp time were 21 and 28 minutes longer, respectively, in Ao-AVR group. Operative mortality was 0.0% in Ao-AVR group, and their early clinical outcomes were comparable to those of Iso-AVR group, except for the occurrence of postoperative atrial fibrillation (46.9% Conclusions: Concomitant ascending aorta replacement during RDAVR demonstrated excellent early and midterm outcomes, comparable to isolated RDAVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.